Global Atopic Dermatitis Drug Market Is Estimated To Witness High Demand Due To Increasing Demand For Biologics And Growing Prevalence Of Atopic Dermatitis
Overview:
Atopic dermatitis is a chronic, inflammatory skin disease that affects a wide range of people. It causes itchy, red, inflamed areas of skin and can occur on any part of the body. It is most common in children and adolescents, although it can also develop in adults. The most common symptoms of atopic dermatitis are itching, inflammation (redness and swelling), dryness, itchiness and cracked, flaky, or crusty skin.
The underlying cause may be related to genetic or environmental factors, it is still unknown. Several drugs are in clinical development for AD, including dupilumab and tralokinumab. These biologics are monoclonal antibodies that mimic the immune system's natural antibodies and work to reduce the symptoms of atopic dermatitis.
Market Dynamics:
Growing product approvals are estimated to augment growth of the global Atopic Dermatitis Drug Market over the forecast period. For instance, Sanofi received approval from the U.S. FDA for Dupixent in June 2022. It is used for treating children between the age group of 6 months to years of age. Moreover, growing side effects of topical steroids is anticipated to restrain growth of the global atopic dermatitis drug for market over the forecast period.
Impact of COVID-19:
COVID-19 was firsts reported in 2019 in China and it was transmitted to other parts of the world. The pandemic resulted in increasing awareness regarding health and hygiene amongst people. People became more conscious regarding their health and well-being. People were using sanitizers and washing their hands regularly, so as to avoid coming in contact with the virus.
Increased the frequency of handwashing, which led to dry skin prone to infections in atopic dermatitis patients. Due to constant exposure to oil-stripping soaps, there was an increase in prevalence of hand eczema. This resulted in increase in demand of moisturizer-based ointments and creams by manufacturers. Thus, the global atopic dermatitis drug for market witnessed robust growth during the pandemic.
Key Takeaways:
The global Atopic Dermatitis Drug Market is expected to witness high growth, exhibiting CAGR of 9.7 % over the forecast period, due to increasing acquisitions.
For instance, Incyte acquired an asset-centric biopharmaceutical company Villaris Therapeutics in October 2022. This acquisition will improve treatment options for people suffering with vitiligo and also increase the company’s expertise.
North America is anticipated to witness significant growth in the global atopic dermatitis drug for market over the forecast period, owing to growing presence of leading players and favorable reimbursement policies.
Major players operating in the global Atopic Dermatitis Drug Market are Incyte Corporation, Pfizer Inc., GALDERMA LABORATORIES, L.P., Regeneron Pharmaceuticals Inc., Sanofi, LEO Pharma Inc., AbbVie Inc., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, and Novartis AG.

Comments
Post a Comment